Abstract
Accumulating evidence suggests that elevated plasma triglycerides concentrations, in both the fasting and the postprandial states, may pose a significant independent risk for cardiovascular disease (CVD). Both fasting and postprandial lipoprotein concentrations vary substantially among individuals, and this interindividual variability is driven by a combination of non-genetic and genetic factors. Regarding the genetic component, the efforts to elucidate the variability in postprandial response have resulted in the identification of associations with multiple lipid candidate genes. However, most reported associations are based on very simple models including one single-nucleotide polymorphism (SNP) or haplotype at a time and small sample sizes. Progress in this promising area of research requires more comprehensive experimental models, including larger sample sizes that will allow investigating gene-gene interactions. Reviews of the literature in the area of ApoA5, GCKR, and PLIN genes and postprandial lipemia are used to demonstrate the complexities of genotype-phenotype associations. Knowledge of how these and other genes influence postprandial response should increase the understanding of personalised nutrition.
Keywords: Gene-diet interaction, nutrigenetics, polymorphism, postprandial lipemia, triglycerides, GCKR gene, cardiovascular disease, ApoA5 gene, PLIN gene, single-nucleotide polymorphism
Current Vascular Pharmacology
Title: Nutrigenetics of the Postprandial Lipoprotein Metabolism: Evidences From Human Intervention Studies
Volume: 9 Issue: 3
Author(s): Pablo Perez-Martinez, Antonio Garcia-Rios, Javier Delgado-Lista, Francisco Perez-Jimenez and Jose Lopez-Miranda
Affiliation:
Keywords: Gene-diet interaction, nutrigenetics, polymorphism, postprandial lipemia, triglycerides, GCKR gene, cardiovascular disease, ApoA5 gene, PLIN gene, single-nucleotide polymorphism
Abstract: Accumulating evidence suggests that elevated plasma triglycerides concentrations, in both the fasting and the postprandial states, may pose a significant independent risk for cardiovascular disease (CVD). Both fasting and postprandial lipoprotein concentrations vary substantially among individuals, and this interindividual variability is driven by a combination of non-genetic and genetic factors. Regarding the genetic component, the efforts to elucidate the variability in postprandial response have resulted in the identification of associations with multiple lipid candidate genes. However, most reported associations are based on very simple models including one single-nucleotide polymorphism (SNP) or haplotype at a time and small sample sizes. Progress in this promising area of research requires more comprehensive experimental models, including larger sample sizes that will allow investigating gene-gene interactions. Reviews of the literature in the area of ApoA5, GCKR, and PLIN genes and postprandial lipemia are used to demonstrate the complexities of genotype-phenotype associations. Knowledge of how these and other genes influence postprandial response should increase the understanding of personalised nutrition.
Export Options
About this article
Cite this article as:
Perez-Martinez Pablo, Garcia-Rios Antonio, Delgado-Lista Javier, Perez-Jimenez Francisco and Lopez-Miranda Jose, Nutrigenetics of the Postprandial Lipoprotein Metabolism: Evidences From Human Intervention Studies, Current Vascular Pharmacology 2011; 9 (3) . https://dx.doi.org/10.2174/157016111795495495
DOI https://dx.doi.org/10.2174/157016111795495495 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Detection of Biothiols Using Some Novel Chemosensors: An Overview
Mini-Reviews in Organic Chemistry Plant Defensins and Defensin-Like Peptides - Biological Activities and Biotechnological Applications
Current Pharmaceutical Design The Role of Brain Gaseous Transmitters in the Regulation of the Circulatory System
Current Pharmaceutical Biotechnology Mesenchymal Stem Cells: New Approaches for the Treatment of Neurological Diseases
Current Stem Cell Research & Therapy Acute Physical Stress Increases Serum Levels of Specific microRNAs
MicroRNA Extended-release Formulation Attenuates the Impacts of Fluvastatin on Serum PCSK9 Levels in Humans
Letters in Drug Design & Discovery Biomarker Discovery and Translation in Metabolomics
Current Metabolomics Taurine, Bone Growth and Bone Development
Current Nutrition & Food Science Endothelial Effects of Drugs Designed to Treat Erectile Dysfunction
Current Pharmaceutical Design Hyperhomocysteinaemia: A Critical Review of Old and New Aspects
Current Drug Metabolism Effect of Rosuvastatin on Non-alcoholic Steatohepatitis in Patients with Metabolic Syndrome and Hypercholesterolaemia: A Preliminary Report
Current Vascular Pharmacology Relevance of Postprandial Lipemia in Metabolic Syndrome
Current Vascular Pharmacology A Direct Correlation between Red Blood Cell Indices and Cognitive Impairment After Aneurysmal Subarachnoid Hemorrhage (aSAH)
Current Neurovascular Research Association between Paraoxonase 1(PON1) Gene Polymorphisms and PON1 Enzyme Activity in Indian Patients with Coronary Artery Disease (CAD)
Current Pharmacogenomics and Personalized Medicine The Polyamine Pathway as a Potential Target for Vascular Diseases: Focus on Restenosis
Current Vascular Pharmacology Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
Current Pharmaceutical Design Impact of Matrix Metalloproteinases on Atherosclerosis
Current Drug Targets The Role of Immunosuppressive Medications in the Pathogenesis of Hypertension and Efficacy and Safety of Antihypertensive Agents in Kidney Transplant Recipients
Current Medicinal Chemistry Application of Mesenchymal Stem Cells to Age-related Neuronal Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT): A Prospective-Randomized Study in Middle Aged Men and Women
Current Vascular Pharmacology